drugset / Trial / NCT04934228

Mitigating the Pro-inflammatory Phenotype of Obesity

NCT04934228

Phase 1 Recruiting 60 enrolled University of Kansas Medical Center
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.

Timeline

Start
2021-07-01
Primary completion
2026-08-01
Completion
2027-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Clonidine Other / unclassified 0.1 mg Oral
Subject Hydrochlorothiazide Unknown 12.5 mg Oral